

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Shanghai Henlius Biotech, Inc.

上海復宏漢霖生物技術股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 2696)

INSIDE INFORMATION ANNOUNCEMENT

LISTING APPROVAL GRANTED BY THE STOCK EXCHANGE FOR THE H SHARE FULL CIRCULATION OF THE COMPANY

This announcement is made by Shanghai Henlius Biotech, Inc. (the “**Company**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

References are made to the announcements of the Company dated 24 March 2025, 9 June 2025 and 16 January 2026 (the “**Announcements**”) in relation to the consideration and approval of the proposed implementation of the H Share Full Circulation by the Board, as well as completion of the filing made by the Company with the CSRC in relation to the proposed implementation of the H Share Full Circulation. Unless otherwise defined, capitalised terms used herein shall have the same meanings as those defined in the Announcements.

LISTING APPROVAL GRANTED BY THE STOCK EXCHANGE

The Board is pleased to announce that, the Company has received the approval granted by the Stock Exchange dated 19 January 2026, for the listing of and permission to deal in 182,645,856 H Shares (the “**Converted H Shares**”), representing the total number of the Unlisted Shares to be converted under the Conversion and Listing.

SHAREHOLDING STRUCTURE UPON COMPLETION OF THE CONVERSION AND LISTING

The Conversion and Listing will involve a total of 17 participating shareholders holding an aggregate of 182,645,856 Unlisted Shares, and the number of Converted H Shares held by the participating shareholders represents approximately 33.61% of the total issued shares of the Company as at the date of this announcement.

Upon completion of the Conversion and Listing, the Converted H Shares shareholding percentages of the participating shareholders in the Company are set out as follows:

Name of participating shareholders	Number of Converted H Shares (shares)	Approximate percentage of total issued shares of the Company upon completion of the H Share Full Circulation (%)
Shanghai Fosun New Medicine Research Company Limited* (上海復星新藥研究股份有限公司)	120,000,000	22.0793
Xiamen Health Hongtu Equity Investment Partnership Enterprise (Limited Partnership)* (廈門健康紅土股權投資合夥企業(有限合夥))	12,479,372	2.2961
Shenzhen Gaotejia Ruiyi Investment Partnership Enterprise (Limited Partnership)* (深圳高特佳睿益投資合夥企業(有限合夥))	10,900,669	2.0057
Chongqing Gaotejia Ruian Equity Investment Fund Partnership Enterprise (Limited Partnership)* (重慶高特佳睿安股權投資基金合夥企業(有限合夥))	6,605,019	1.2153
Jiaxing Shenmao No.8 Equity Investment Partnership Enterprise (Limited Enterprise)* (嘉興申貿捌號股權投資合夥企業(有限合夥))	5,835,229	1.0736
Shanghai Founder KIP Equity Investment Partnership (Limited Partnership)* (上海方正韓投股權投資合夥企業(有限合夥))	5,714,310	1.0514
Hangzhou Fuhong Equity Investment Partnership Enterprise (Limited Partnership)* (杭州復宏股權投資合夥企業(有限合夥))	4,567,200	0.8403
Gongqingcheng Yingshuo Henlius Investment Fund Partnership Enterprise (Limited Partnership)* (共青城英碩漢霖投資基金合夥企業(有限合夥))	4,376,422	0.8052
Liqi Pan* (盤李琦)	4,376,422	0.8052
Shanghai Tanying Investment Partnership Enterprise (Limited Partnership)* (上海檀英投資合夥企業(有限合夥))	4,050,000	0.7452
Zhoushan Guohong Biotech Partnership Enterprise (Limited Partnership)* (舟山果宏生物技術合夥企業(有限合夥))	1,114,295	0.2050
Zhuhai Shenhong Gejin Healthcare Investment Fund Partnership (Limited Partnership)* (珠海申宏格金醫療健康產業投資基金合夥企業(有限合夥))	606,060	0.1115

Name of participating shareholders	Number of Converted H Shares (shares)	Approximate percentage of total issued shares of the Company upon completion of the H Share Full Circulation (%)
Huagai Medical Health Venture Capital Investment Chengdu Partnership Enterprise (Limited Partnership)* (華蓋醫療健康創業投資成都合夥企業 (有限合夥))	556,621	0.1024
Huagai Medical Investment Management Beijing Co., Ltd.* (華蓋醫療投資管理(北京)有限公司)	535,502	0.0985
Zhoushan Guoyou Biotech Partnership Enterprise (Limited Partnership)* (舟山果友生物技術合夥 企業(有限合夥))	508,235	0.0935
Huaqi Fund Management (Hangzhou) CO., LTD* (華旗私募基金管理(杭州)有限公司)	270,500	0.0498
Shanghai Qiangang Investment Management Partnership Enterprise (Limited Partnership)* (上海乾剛投資管理合夥企業(有限合夥))	150,000	0.0276
Total	182,645,856	33.6058

Note: In this announcement, any discrepancies between totals and sums of figures listed are due to rounding.

The shareholding structure of the Company as at the date of this announcement and immediately upon completion of the Conversion and Listing is set out below:

Type of Shares	As at the date of this announcement		Immediately upon completion of the Conversion and Listing	
	Number of Shares (shares)	Approximate percentage of the total number of issued shares of the Company (%)	Number of Shares (shares)	Approximate percentage of the total number of issued shares of the Company (%)
Unlisted Shares	380,066,312	69.93	197,420,456	36.32
H Shares	163,428,541	30.07	346,074,397	63.68
Total	543,494,853	100	543,494,853	100

The Company shall complete the relevant conversion and trading procedures in respect of the Converted H Shares and will make further announcement(s) on the progress of the H Share Full Circulation and the Conversion and Listing in accordance with the requirements under the Listing Rules and applicable laws, as and when appropriate.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares and other securities of the Company.

On behalf of the Board
Shanghai Henlius Biotech, Inc.
Wenjie Zhang
Chairman

Hong Kong, 19 January 2026

As at the date of this announcement, the board of directors of the Company comprises Mr. Wenjie Zhang as the chairman and non-executive director, Dr. Jun Zhu as the executive director, Mr. Qiyu Chen, Mr. Yuqing Chen, Ms. Xiaohui Guan, Dr. Yi Liu and Dr. Xingli Wang as the non-executive directors, and Mr. Tak Young So, Dr. Lik Yuen Chan, Dr. Ruilin Song and Mr. Yihao Zhang as the independent non-executive directors.

* *for identification purposes only*